SubHero Banner
Text

Keytruda® (pembrolizumab) – Updated indication

August 31, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.

Download PDF